Viewing Study NCT06057922



Ignite Creation Date: 2024-05-06 @ 7:34 PM
Last Modification Date: 2024-10-26 @ 3:09 PM
Study NCT ID: NCT06057922
Status: RECRUITING
Last Update Posted: 2023-12-20
First Post: 2023-09-21

Brief Title: A Study YL201 in Patients With Selected Advanced Solid Tumors
Sponsor: MediLink Therapeutics Suzhou Co Ltd
Organization: MediLink Therapeutics Suzhou Co Ltd

Study Overview

Official Title: A Multicenter Open-Label Phase 12 Study to Evaluate the Safety Efficacy and Pharmacokinetics of YL201 in Patients With Selected Advanced Solid Tumors
Status: RECRUITING
Status Verified Date: 2023-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is A Multicenter Open-Label Phase 12 Study to Evaluate the Safety Efficacy and Pharmacokinetics of YL201 in Patients with Selected Advanced Solid Tumors The study will include 2 parts Phase 1 dose expansion stage Part 1 followed by a Phase 2 stage with expanded sample size Part 2

Part 1 will estimate the RP2D in dose expansion cohorts of patients with not linited to non-small cell lung cancer NSCLC small cell lung cancer SCLC nasopharyngeal carcinoma NPC esophageal squamous cell carcinoma ESCC metastatic castration-resistant prostate cancer mCRPC etc

Part 2 will include patients with selected advanced solid tumor types enrolled at the RP2D to further assess the efficacy and safety of YL201
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None